Efficacy of antiplatelets in deep venous thrombosis
Venous thromboembolism (VTE) is the third most common cardiovascular disease in the world. Every year, 30,000 people in Australia develop VTE, at a cost of $1.72 billion to the Australian health system.
Complementary medicines: Heart failure
Heart failure (HF), also referred to as congestive cardiac failure, is present in 1–2% of the Australian population.1 It is the end result of...
The impact of air pollution
Air pollution is making us sick according to local and global research, including a study linking exposure to air pollution with subsequent acute cardiac...
Inside a multidisciplinary antenatal vaccination clinic
To protect pregnant women and their unborn babies from the severe adverse outcomes associated with the virus, the first pharmacist-led COVID-19 vaccination clinic for pregnant women opened in Western Australia’s King Edward Memorial Hospital on 20 September.
Psychotropic self-poisoning on the rise in youth
A new retrospective cohort study has found that self-poisoning, by ingesting psychotropic medicines, in Australian children and adolescents is increasing. The prescribed medicines...
New Parliamentary Friendship Group champions safer medicines use
The PSA has supported the launch of the inaugural Parliamentary Friends of Safe and Quality Use of Medicines event, using the opportunity to call...













